Rodrigues J, Campos G, Bittar C, Martinelli A, Campos M, Pereira L
Braz J Infect Dis. 2022; 26(6):102717.
PMID: 36410397
PMC: 9706524.
DOI: 10.1016/j.bjid.2022.102717.
Singh D, Soni S, Khan S, Sarangi A, Yennamalli R, Aggarwal R
J Virol. 2019; 94(3).
PMID: 31723027
PMC: 7000968.
DOI: 10.1128/JVI.01327-19.
Underwood A, Walker M, Brasher N, Eltahla A, Maher L, Luciani F
Viruses. 2018; 10(11).
PMID: 30469363
PMC: 6266478.
DOI: 10.3390/v10110659.
Zheng J, Liang H, Xu C, Xu Q, Zhang T, Shen T
Cell Mol Immunol. 2014; 11(3):294-304.
PMID: 24531620
PMC: 4085489.
DOI: 10.1038/cmi.2013.70.
Ma C, Ren J, Li G, Wu X, Brockstedt D, Lauer P
PLoS One. 2014; 9(1):e87821.
PMID: 24498204
PMC: 3909257.
DOI: 10.1371/journal.pone.0087821.
On hepatitis C virus evolution: the interaction between virus and host towards treatment outcome.
Bittar C, Jardim A, Yamasaki L, Carareto C, Pinho J, Lemey P
PLoS One. 2013; 8(4):e62393.
PMID: 23638063
PMC: 3636177.
DOI: 10.1371/journal.pone.0062393.
Unique Cytokine/Chemokine Signatures for HIV-1 and HCV Mono-infection versus Co-infection as Determined by the Luminex® Analyses.
Rahman S, Connolly J, Manuel S, Chehimi J, Montaner L, Jain P
J Clin Cell Immunol. 2011; 2(1).
PMID: 21866203
PMC: 3134230.
DOI: 10.4172/2155-9899.1000104.
Hepatitis C virus NS5B protein delays s phase progression in human hepatocyte-derived cells by relocalizing cyclin-dependent kinase 2-interacting protein (CINP).
Wang Y, Wang Y, Xu Y, Tong W, Pan T, Li J
J Biol Chem. 2011; 286(30):26603-15.
PMID: 21628470
PMC: 3143625.
DOI: 10.1074/jbc.M111.225672.
Mechanisms of viral emergence.
Domingo E
Vet Res. 2010; 41(6):38.
PMID: 20167200
PMC: 2831534.
DOI: 10.1051/vetres/2010010.
Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.
Mancini N, Diotti R, Perotti M, Sautto G, Clementi N, Nitti G
PLoS One. 2009; 4(12):e8254.
PMID: 20011511
PMC: 2785886.
DOI: 10.1371/journal.pone.0008254.
Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.
Yuan H, Jain M, Snow K, Gale Jr M, Lee W
J Viral Hepat. 2009; 17(3):208-16.
PMID: 19656286
PMC: 3189487.
DOI: 10.1111/j.1365-2893.2009.01169.x.
Separation of Hepatitis C genotype 4a into IgG-depleted and IgG-enriched fractions reveals a unique quasispecies profile.
Moreau I, OSullivan H, Murray C, Levis J, Crosbie O, Kenny-Walsh E
Virol J. 2008; 5:103.
PMID: 18811965
PMC: 2561023.
DOI: 10.1186/1743-422X-5-103.
Underlying pathophysiology of HCV infection in HIV-positive drug users.
Balasubramanian A, Groopman J, Ganju R
J Addict Dis. 2008; 27(2):75-82.
PMID: 18681194
PMC: 2720610.
DOI: 10.1300/J069v27n02_09.
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.
Moreau I, Levis J, Crosbie O, Kenny-Walsh E, Fanning L
Virol J. 2008; 5:78.
PMID: 18613968
PMC: 2483966.
DOI: 10.1186/1743-422X-5-78.
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus.
Russell R, Meunier J, Takikawa S, Faulk K, Engle R, Bukh J
Proc Natl Acad Sci U S A. 2008; 105(11):4370-5.
PMID: 18334634
PMC: 2393785.
DOI: 10.1073/pnas.0800422105.
High levels of subgenomic HCV plasma RNA in immunosilent infections.
Bernardin F, Stramer S, Rehermann B, Page-Shafer K, Cooper S, Bangsberg D
Virology. 2007; 365(2):446-56.
PMID: 17493654
PMC: 2001282.
DOI: 10.1016/j.virol.2007.04.003.
Quasispecies and its impact on viral hepatitis.
Domingo E, Gomez J
Virus Res. 2007; 127(2):131-50.
PMID: 17349710
PMC: 7125676.
DOI: 10.1016/j.virusres.2007.02.001.
Evolution of the uniquely adaptable lentiviral envelope in a natural reservoir host.
Demma L, Vanderford T, Logsdon Jr J, Feinberg M, Staprans S
Retrovirology. 2006; 3:19.
PMID: 16549011
PMC: 1431560.
DOI: 10.1186/1742-4690-3-19.
